Roundup: Singapore-based medical startup Oncoshot secures funding to expand to India, Australia, and more
Oncoshot receives funding to further expand in India and Australia
Singapore-based medical startup Oncoshot has secured an undisclosed investment through a pre-Series A funding round led by Biofurmis and Qure.ai investor MassMutual Ventures.
According to a press release, the financing will support further expansion of the company in India and Australia.
There are four hospital networks in India and some networks of more than 20 hospitals in Oceania that are in the process of creating their respective nationwide public-private clinical trial ecosystems, such as the Singapore EISE Project. The latter uses Oncoshot’s clinical trial comparison platform to connect cancer patients, healthcare professionals, and pharmaceutical and biotech companies.
Clinical trials worldwide are said to lose an estimated $35 billion annually due to inefficient processes in cancer research and patient recruitment.
Oncoshot has developed a solution to these problems by enhancing clinical partners’ medical records through artificial intelligence and machine learning. Its federated data system securely houses critical and confidential patient data within hospital facilities and provides complete analytics and information protection, access and control to hospital administrators.
Happiest Health health knowledge website goes online in India
Indian IT consulting and services firm, Happiest Minds Technologies, has launched a new online repository of health and wellness knowledge and information.
Called Happiest Health, the website aims to provide “in-depth, credible and trustworthy” information on health and wellness, according to a press release.
You will educate your audience with discoveries and developments in health and wellness, coming from new research and studies from global partner institutes. The portal will also highlight new tools for early detection, as well as user stories and feedback.
In addition, a group of physicians and wellness experts will contribute essays and guest articles that offer unique perspectives and interesting medical experiences.
“Through Happiest Health, we want to reinforce the importance of integrated medicine, provide valuable knowledge through experts in early diagnosis and evidence-based therapies, and do so with empathy and passion,” said Ashok Soota, President of Happiest Health.
Within the next year, the website will publish written and video content in regional languages to cater to lower-tier Indian cities. Happiest Health will also launch a podcast, web series and audio content soon.
Clinical trials in India confirm efficacy of AI in detection of attributable glaucoma
Indian medical device manufacturer Remidio Innovative Solutions has reported positive results from separate clinical trials of its AI solution to detect attributable glaucoma.
Remidio offers an integrated screening solution for remissible glaucoma, a stage where the disease can still be better controlled through treatment. It consists of a fundus on the phone, a retinal imaging device, and an AI algorithm for offline inference. Means Referable Glaucoma AI detects structural changes in the optic nerve head and the surrounding retinal nerve fiber layer.
According to a press release, the entire detection process takes only 15 seconds.
The company recently partnered with two local eye hospitals, Aravind Eye Hospital in Pondicherry and Narayana Nethralaya (NN) in Bangalore, to trial its screening solution.
In the clinical trial in NN, the AI algorithm was found to achieve a high sensitivity of 93.5% and a high specificity of 85.4% in detecting attributable glaucoma, while early results from the clinical trial in Aravind showed that the algorithm also achieves high sensitivity and specificity of 91.3% and 91.67%, respectively.
The company noted that while there are treatment options to control remissionable glaucoma, simple screening tests are hard to come by. Currently, glaucoma specialists are still conducting a series of complex investigations using multiple devices to detect attributable glaucoma.
“The promising results show that our artificial intelligence can enable health professionals and ophthalmologists in general to make an objective screening diagnosis, particularly in centers that lack sophisticated diagnostic equipment,” said Dr. Divya Rao, medical director and Remidio’s AI boss.
- Click to share on Twitter (Opens in a new window)
- Click to share on Facebook (Opens in a new window)
- Click to share on LinkedIn (Opens in a new window)
- Click to share on WhatsApp (Opens in a new window)